Carbohydrate Metabolism Practice Questions

Q: What is the primary metabolic consequence of pyruvate carboxylase deficiency?

Decreased gluconeogenesis leading to hypoglycemia. ***Decreased gluconeogenesis leading to hypoglycemia*** - Pyruvate carboxylase catalyzes the conversion of **pyruvate to oxaloacetate**, the first committed step of **gluconeogenesis**. - A deficiency impairs glucose synthesis from non-carbohydrate sources, leading to severe **fasting hypoglycemia**, especially in neonates and infants. - This represents the PRIMARY defect in the **metabolic pathway** for glucose homeostasis. *Increased glycolysis due to energy demand* - Pyruvate carboxylase deficiency does not directly increase glycolysis. - In fact, **hypoglycemia** would limit glucose availability for glycolysis, making this option incorrect. - The deficiency affects gluconeogenesis (glucose synthesis), not glycolysis (glucose breakdown). *Accumulation of pyruvate due to blocked conversion* - While pyruvate does accumulate when its conversion to oxaloacetate is blocked, this is an **intermediate biochemical finding** rather than the primary metabolic consequence. - The clinically significant outcomes are what happens **downstream**: impaired glucose production and increased lactate formation. *Increased lactic acid production due to impaired gluconeogenesis* - This is indeed a **major clinical consequence** of pyruvate carboxylase deficiency, causing severe **lactic acidosis**. - Accumulated pyruvate is shunted to lactate via lactate dehydrogenase. - However, when specifically asking for the PRIMARY **metabolic consequence** of the enzyme deficiency itself, it is the **impaired gluconeogenesis** (the direct pathway affected) that is most primary, with lactic acidosis being a consequent metabolic derangement from the accumulated substrate.

Q: A child presents with hepatomegaly, hypoglycemia, and lactic acidosis. Genetic testing confirms a deficiency in glucose-6-phosphatase. What disease does this indicate?

Von Gierke disease. ***Von Gierke disease*** - This disease is directly caused by a **deficiency of glucose-6-phosphatase**, leading to the characteristic accumulation of **glycogen in the liver** and kidneys. - The deficiency prevents the release of glucose from glycogen stores, resulting in **hypoglycemia** and a compensatory increase in other metabolic pathways, causing **lactic acidosis**. *Pompe disease* - Caused by a deficiency of **acid α-glucosidase (acid maltase)**, leading to glycogen accumulation primarily in **lysosomes** in muscles, including the heart. - While it involves glycogen storage and can cause **cardiomyopathy** and muscle weakness, it does not typically present with severe hypoglycemia or lactic acidosis in the same way as Von Gierke disease. *Cori disease* - Also known as **Glycogen Storage Disease Type III**, it results from a deficiency in the **glycogen debranching enzyme**. - Patients present with **hepatomegaly**, hypoglycemia, and sometimes muscle weakness, but usually have less severe lactic acidosis than Von Gierke disease and a distinctive short outer chain glycogen structure. *Andersen disease* - Also known as **Glycogen Storage Disease Type IV**, it is caused by a deficiency in the **glycogen branching enzyme**. - This leads to the storage of **abnormal glycogen molecules** (long unbranched chains) primarily in the liver and muscles, often presenting with **cirrhosis** and liver failure, and not typically with severe hypoglycemia or lactic acidosis as the primary metabolic derangement.

Q: An individual with a rare metabolic disorder exhibits elevated levels of pyruvate and alanine in the blood. This suggests a defect in which enzyme involved in gluconeogenesis?

Pyruvate carboxylase. ***Pyruvate carboxylase*** - **Pyruvate carboxylase** converts **pyruvate** to **oxaloacetate** in gluconeogenesis. A defect will cause a buildup of its substrate, **pyruvate**, and its transamination product, **alanine**. - This enzyme is crucial for diverting pyruvate from **glycolysis** towards glucose synthesis in the liver and kidneys. *Phosphoenolpyruvate carboxykinase* - This enzyme converts **oxaloacetate** to **phosphoenolpyruvate (PEP)**. A defect would lead to elevated oxaloacetate, not pyruvate or alanine. - While essential for gluconeogenesis, its malfunction would manifest differently from the given elevated substrate levels. *Fructose-1,6-bisphosphatase* - This enzyme catalyzes the dephosphorylation of **fructose-1,6-bisphosphate** to **fructose-6-phosphate**. A defect would cause an accumulation of fructose-1,6-bisphosphate. - This step occurs further down the gluconeogenic pathway and would not directly lead to elevated pyruvate or alanine. *Glucose-6-phosphatase* - **Glucose-6-phosphatase** converts **glucose-6-phosphate** to **free glucose**, the final step in both gluconeogenesis and glycogenolysis. - A defect would result in the accumulation of **glucose-6-phosphate** and **hypoglycemia**, not elevated pyruvate or alanine.

Q: A patient with severe fasting hypoglycemia and hepatomegaly is diagnosed with von Gierke's disease. Which enzyme deficiency is responsible for this condition?

Glucose-6-phosphatase. ***Glucose-6-phosphatase*** - **Von Gierke's disease** (Glycogen Storage Disease Type I) is characterized by a deficiency of **glucose-6-phosphatase**, an enzyme crucial for the final step of both **glycogenolysis** and **gluconeogenesis**. - This deficiency prevents the release of free glucose from the liver into the bloodstream, leading to severe **fasting hypoglycemia** and the accumulation of glycogen in the liver, causing **hepatomegaly**. *Glycogen synthase* - A deficiency in **glycogen synthase** would lead to an inability to synthesize glycogen, resulting in **hypoglycemia** but without the characteristic **hepatomegaly** due to glycogen accumulation. - This condition is known as **Glycogen Storage Disease Type 0**, and it typically presents with fasting hypoglycemia due to insufficient liver glycogen stores, but not excess, unlike Von Gierke's. *Debranching enzyme* - A deficiency in the **debranching enzyme** (α-1,6-glucosidase) is associated with **Cori's disease** (Type III Glycogen Storage Disease). - This leads to the accumulation of **abnormally short glycogen branches**, causing **hepatomegaly** and milder hypoglycemia, but the hypoglycemia is usually not as severe as in Von Gierke's. *Branching enzyme* - A deficiency in the **branching enzyme** (amylo-(1,4 to 1,6)-transglucosidase) is seen in **Andersen's disease** (Type IV Glycogen Storage Disease). - This results in the formation of **unbranched glycogen polymers**, which are less soluble and tend to precipitate, causing **liver cirrhosis** and failure rather than severe fasting hypoglycemia as the primary metabolic issue.

Q: A patient with chronic granulomatous disease has recurrent bacterial infections. Which biochemical pathway is defective?

Pentose phosphate pathway. ***Pentose phosphate pathway*** - Chronic granulomatous disease (CGD) is characterized by a defect in **NADPH oxidase**, the enzyme responsible for the respiratory burst in phagocytes. - While the defect is in NADPH oxidase itself, the **pentose phosphate pathway** is functionally critical because it is the primary source of **NADPH**, the essential substrate for NADPH oxidase. - Without adequate NADPH production, even functional NADPH oxidase cannot generate superoxide radicals needed to kill bacteria. - This makes the pentose phosphate pathway the most relevant metabolic pathway connected to CGD pathology among the options listed. *TCA cycle* - The **TCA cycle (Krebs cycle)** is central to aerobic respiration and produces ATP through oxidative metabolism. - It is not directly linked to phagocyte respiratory burst or the pathology of CGD. - Defects in the TCA cycle typically lead to severe metabolic dysfunction affecting overall energy production, not specifically immune cell bactericidal function. *Beta-oxidation* - **Beta-oxidation** is the process by which fatty acids are broken down to produce acetyl-CoA and generate energy. - While critical for energy metabolism, it is not implicated in the immune dysfunction or respiratory burst defect seen in CGD. *Glycogenolysis* - **Glycogenolysis** is the breakdown of glycogen into glucose, primarily for maintaining blood glucose levels and providing energy. - Defects in this pathway cause glycogen storage diseases, which present with hepatomegaly, hypoglycemia, or muscle weakness. - These disorders do not involve recurrent bacterial infections due to impaired phagocyte bactericidal function.

Q: Which enzyme deficiency is associated with a history of vomiting, irritability, and jaundice in infants?

Galactose-1-phosphate uridyl transferase. ***Galactose-1-phosphate uridyl transferase*** - Deficiency in **galactose-1-phosphate uridyl transferase** (GALT) causes **classic galactosemia**, leading to the accumulation of toxic galactose metabolites. - This accumulation results in symptoms such as **vomiting, irritability, jaundice, hepatomegaly, cataracts**, and poor feeding in infants once they start consuming milk. *Fructokinase* - Deficiency of **fructokinase** causes **essential fructosuria**, a benign condition where fructose is excreted in the urine. - It is typically **asymptomatic** and does not lead to severe symptoms like vomiting or jaundice. *Aldolase B* - Deficiency of **aldolase B** causes **hereditary fructose intolerance**, leading to severe symptoms upon ingestion of fructose, sucrose, or sorbitol. - While it can manifest with vomiting and jaundice, the clinical picture usually develops **after initial exposure to fructose-containing foods**, which might not be immediate in infants (e.g., when complementary feeding starts). *Alpha glucosidase* - Deficiency of **alpha glucosidase** (also known as acid maltase) causes **Pompe disease** (Type II glycogen storage disease). - This lysosomal storage disorder primarily affects muscle function, leading to **cardiomegaly**, **hypotonia**, and muscle weakness, not typically early-onset vomiting and jaundice without other prominent muscular symptoms.

Q: Evaluate the metabolic impact of a mutation in the gene encoding pyruvate dehydrogenase. Which dietary intervention would be most appropriate for managing the symptoms?

High-fat diet. ***High-fat diet*** - A mutation in **pyruvate dehydrogenase (PDH)** impairs the conversion of pyruvate to acetyl-CoA, thus preventing carbohydrates from being efficiently used for energy via the **Krebs cycle**. - A **high-fat diet** provides an alternative energy source through **beta-oxidation of fatty acids**, which produces acetyl-CoA directly, bypassing the defective PDH complex and supporting ATP production. *High-carbohydrate diet* - This would exacerbate the metabolic problems, as carbohydrates are broken down into **pyruvate**, which cannot be efficiently processed due to the compromised **pyruvate dehydrogenase complex**. - It would lead to an accumulation of **lactic acid** and **pyruvate**, contributing to **lactic acidosis** and neurological dysfunction. *High-protein diet* - While amino acids can enter the Krebs cycle at various points, a **high-protein diet** is not the primary or most efficient bypass for a **pyruvate dehydrogenase deficiency**. - Excessive protein intake can also lead to other metabolic burdens, such as increased nitrogenous waste, which may not be ideal. *Low-fat diet* - A **low-fat diet** would limit the primary alternative energy source for individuals with compromised **pyruvate dehydrogenase**, thus worsening energy deficits. - It would force the body to rely more heavily on the impaired carbohydrate metabolism, leading to more severe symptoms.

Q: A patient with hypoglycemia and hepatomegaly is found to have a defect in the enzyme glucose-6-phosphatase. What is the metabolic impact of this deficiency?

Impaired gluconeogenesis and glycogenolysis. ***Impaired gluconeogenesis and glycogenolysis*** - Glucose-6-phosphatase is essential for the final step in both **gluconeogenesis** and **glycogenolysis**, converting glucose-6-phosphate to free glucose for release into the bloodstream. - A deficiency in this enzyme, characteristic of **Von Gierke disease (Type I glycogen storage disease)**, prevents the liver from producing and releasing sufficient glucose, leading to **hypoglycemia** and **hepatomegaly** due to accumulated glycogen. *Increased glycogen synthesis* - While glycogen accumulates in the liver due to the inability to break it down, the primary defect isn't an *increase* in synthesis but rather a block in the **breakdown and release** of glucose. - Glycogen synthase activity might even be indirectly affected by the buildup of glucose-6-phosphate, but the core metabolic impact is impaired release. *Enhanced glycolysis* - Glycolysis is the breakdown of glucose, and while some extra glucose-6-phosphate might be shunted towards glycolysis, the overall metabolic picture is dominated by the inability to *produce* glucose from stores or other precursors. - The liver's main role in maintaining blood glucose means impaired glucose release has a far greater systemic impact. *Decreased lipid metabolism* - This deficiency actually leads to **increased lipid synthesis** and **hyperlipidemia**, not decreased lipid metabolism. - The accumulation of glucose-6-phosphate promotes divergent pathways like the **pentose phosphate pathway** and subsequent increase in acetyl-CoA, which serves as a precursor for fatty acid synthesis.

Q: Galactosemia is due to deficiency of which enzyme?

Galactose-1-phosphate uridyltransferase. ***Galactose-1-phosphate uridyltransferase*** - Deficiency of **galactose-1-phosphate uridyltransferase (GALT)** leads to the most severe form, **classic galactosemia**. - This enzyme is crucial for converting **galactose-1-phosphate** to **glucose-1-phosphate** in the Leloir pathway. *HGPRT* - **HGPRT** (hypoxanthine-guanine phosphoribosyltransferase) deficiency causes **Lesch-Nyhan syndrome**, a distinct metabolic disorder. - Lesch-Nyhan syndrome is characterized by **hyperuricemia**, neurological dysfunction, and self-mutilation, unrelated to galactose metabolism. *Galactokinase* - Deficiency of **galactokinase** causes Type II galactosemia, a milder form than classic galactosemia. - This defect primarily leads to **cataracts** due to galactitol accumulation but does not result in the severe systemic issues seen in classic galactosemia. *Epimerase* - Deficiency of **UDP-galactose-4'-epimerase** (GALE) causes Type III galactosemia, which has a variable clinical presentation from mild to severe. - While involved in galactose metabolism, it's not the primary enzyme deficient in the most common and severe form of **galactosemia**.

Q: A 3 months old child was started on supplemental foods along with breastmilk. The child was fed with fruit pulp and sweetened cereals. Soon the child developed bloating of abdomen, vomiting, lethargy, and irritability. On investigation, there was hyperbilirubinemia and elevated transaminase levels. The child is suffering from which of the following enzyme deficiencies?

Aldolase B. ***Aldolase B*** - This presentation is characteristic of **hereditary fructose intolerance**, an autosomal recessive disorder caused by a deficiency of **aldolase B**. - Infants typically appear normal until fructose or sucrose (hydrolyzed to glucose and fructose) is introduced into their diet, leading to symptoms like **vomiting**, **bloating**, **lethargy**, and **liver and kidney dysfunction** (hyperbilirubinemia, elevated transaminases). ***Fructokinase*** - Deficiency in fructokinase causes **essential fructosuria**, a benign condition where fructose accumulates in the blood and urine. - It does not lead to the severe gastrointestinal or hepatic symptoms described, as fructose metabolism is not completely blocked. ***Galactokinase*** - Deficiency of galactokinase results in **Type II galactosemia**, primarily causing **cataracts** due to galactitol accumulation. - While galactosemia can present with liver dysfunction, it typically involves lactose intolerance from breastmilk or formula and doesn't align with the introduction of fruit pulp and sweetened cereals as the trigger. ***Galactose-1-phosphate uridyl transferase*** - Deficiency of this enzyme causes **Classic Galactosemia (Type I)**, a severe genetic disorder often diagnosed early due to intolerance to lactose in breast milk or formula. - Symptoms include **vomiting**, **jaundice**, **hepatomegaly**, and **failure to thrive**, with potential for severe complications if untreated. However, the trigger of fruit pulp and sweetened cereals (sources of fructose/sucrose) more strongly points away from galactosemia and towards fructose intolerance.

Question 1

What is the primary metabolic consequence of pyruvate carboxylase deficiency?

Accepted Answer

Decreased gluconeogenesis leading to hypoglycemia

Answer

Increased glycolysis due to energy demand

Answer

Accumulation of pyruvate due to blocked conversion

Answer

Increased lactic acid production due to impaired gluconeogenesis

Question 2

A child presents with hepatomegaly, hypoglycemia, and lactic acidosis. Genetic testing confirms a deficiency in glucose-6-phosphatase. What disease does this indicate?

Accepted Answer

Von Gierke disease

Answer

Pompe disease

Answer

Cori disease

Answer

Andersen disease

Question 3

An individual with a rare metabolic disorder exhibits elevated levels of pyruvate and alanine in the blood. This suggests a defect in which enzyme involved in gluconeogenesis?

Accepted Answer

Pyruvate carboxylase

Answer

Phosphoenolpyruvate carboxykinase

Answer

Fructose-1,6-bisphosphatase

Answer

Glucose-6-phosphatase

Question 4

A patient with severe fasting hypoglycemia and hepatomegaly is diagnosed with von Gierke's disease. Which enzyme deficiency is responsible for this condition?

Accepted Answer

Glucose-6-phosphatase

Answer

Glycogen synthase

Answer

Debranching enzyme

Answer

Branching enzyme

Question 5

A patient with chronic granulomatous disease has recurrent bacterial infections. Which biochemical pathway is defective?

Accepted Answer

Pentose phosphate pathway

Answer

TCA cycle

Answer

Beta-oxidation

Answer

Glycogenolysis

Question 6

Which enzyme deficiency is associated with a history of vomiting, irritability, and jaundice in infants?

Accepted Answer

Galactose-1-phosphate uridyl transferase

Answer

Fructokinase

Answer

Aldolase B

Answer

Alpha glucosidase

Question 7

Evaluate the metabolic impact of a mutation in the gene encoding pyruvate dehydrogenase. Which dietary intervention would be most appropriate for managing the symptoms?

Accepted Answer

High-fat diet

Answer

High-carbohydrate diet

Answer

High-protein diet

Answer

Low-fat diet

Question 8

A patient with hypoglycemia and hepatomegaly is found to have a defect in the enzyme glucose-6-phosphatase. What is the metabolic impact of this deficiency?

Accepted Answer

Impaired gluconeogenesis and glycogenolysis

Answer

Increased glycogen synthesis

Answer

Enhanced glycolysis

Answer

Decreased lipid metabolism

Question 9

Galactosemia is due to deficiency of which enzyme?

Accepted Answer

Galactose-1-phosphate uridyltransferase

Answer

HGPRT

Answer

Galactokinase

Answer

Epimerase

Question 10

A 3 months old child was started on supplemental foods along with breastmilk. The child was fed with fruit pulp and sweetened cereals. Soon the child developed bloating of abdomen, vomiting, lethargy, and irritability. On investigation, there was hyperbilirubinemia and elevated transaminase levels. The child is suffering from which of the following enzyme deficiencies?

Accepted Answer

Aldolase B

Answer

Fructokinase

Answer

Galactose - 1 - phosphate uridyl transferase

Answer

Galactokinase

Carbohydrate Metabolism — MCQs

Carbohydrate Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?